IP Library Granted Patent US 7,829,594
Granted Patent B2
US 7,829,594 · App. 12/393,284 · Granted Nov 9, 2010

Calcilytic compounds

Assignee: GlaxoSmithKline, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,829,594
App. No.
12/393,284
Granted
Nov 9, 2010
Kind
B2
Abstract

Novel calcilytic compounds and methods of using them are provided.

Claims (3)

1. A method of increasing serum parathyroid hormone levels in mammals, which comprises the administration to a mammal in need thereof an effective amount of 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxyl]-phenyl}-propionic acid.

2. A method of increasing serum parathyroid hormone levels in mammals, which comprises the administration to a mammal in need thereof an effective amount of a pharmaceutically acceptable salt of the compound 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid.

3. A method of increasing serum parathyroid hormone levels in mammals, which comprises the administration to a mammal in need thereof an effective amount of 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxy]-phenyl}-propionic acid hydrochloride.

Assignments (1)
CHANGE OF NAME Recorded Jul 2, 2010
From: SMITHKLINE BEECHAM CORPORATION
To: GLAXOSMITHKLINE LLC
Reel/Frame 024629/0118 →
Continuity (3)
Division 1053641600
Provisional Application 6042910500 · Nov 26, 2002
Related Publication 20090163589A1 · Jun 25, 2009